Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10537208 | Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics | 2014 | 5 Pages |
Abstract
Biotherapeutics have been clinically used since the 1990s. Recently, next-generation optimized biotherapeutics, which are expected to act on the same molecular target as their predecessors with further properties by antibody-drug conjugation, radiolabeling, PEGylation and glycoconjugation, are on the market. This article reviews recent next-generation optimized biotherapeutics. Moreover, since trials of protein engineering for biotherapeutics have been conducted, these preclinical approaches are also described. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.
Keywords
ADCCTNFCC chemokine receptor 4ATLADCCDRCDCCCR4EPOADAsanti-drug antibodiesantibody-dependent cell-mediated cytotoxicityerythropoietinChemical modificationBiotherapeuticcomplement-dependent cytotoxicityFabtumor necrosis factorantigen binding fragmentcomplementary determining regionProtein engineeringAntibodypolyethyleneglycolPEGAntibody drug conjugate
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Tadashi Ueda,